



# Auro Laboratories Limited

314, T. V. Industrial Estate, S.K. Ahire Marg,  
Worli, Mumbai - 400 030. India  
Tel. : + 91 22 6663 5456  
Fax : +91 22 6663 5460  
E-mail : auro@aurolabs.com  
Web : www.aurolabs.com

Reg. Off. / Mfg. Unit :  
K-56, M. I. D. C. Tarapur,  
Dist. Palghar, Maharashtra - 401506.  
CIN No. L33125MH1989PLC051910

**Date: February 07 2018**

To  
BSE Limited,  
Corporate Relationship Department,  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai - 400 001

**Reg: Security Code No. 530233**

**Sub: Outcome of the Board Meeting**  
**Unaudited Financial Results for the Quarter year ended December 31, 2017 in**  
**compliance with Regulation 30 & Regulation 33 of the SEBI (LODR) Regulations, 2015:**

Dear Sir,

Pursuant to Regulation 30 & Regulation 33 of SEBI (LODR) Regulations, 2015, we wish to inform you that the Board of Directors at their Meeting held today (i.e. Wednesday, February 07, 2018), has approved the Unaudited Financial Results along with Limited Review Report for the quarter ended December 31, 2017.

In this regard, we are enclosing herewith:

- Unaudited Financial Results for the Quarter year ended December 31, 2017.
- Limited Review Report received from the Statutory Auditor of the Company.

The Meeting of the Board commenced at 2.00 P. M. and concluded at 2.50 P. M. The results will be published in the newspaper pursuant to Regulation 47(1)(b) of SEBI (LODR) Regulations, 2015 in due course.

Kindly take the same on record and acknowledge.

Thanking You,  
Yours Faithfully,  
For AURO LABORATORIES LIMITED

  
**SHARAT DEORAH**  
**CHAIRMAN & MANAGING DIRECTOR**  
DIN: 00230784  
Encl.: as above

**AURO LABORATORIES LIMITED**  
CIN NO. :- L33125MH1989PLC051910

Regd. Office : K - 56 M.I.D.C INDUSTRIAL AREA, TARAPUR  
BOISAR, DIST. PALGHAR 401506, MAHARASHTRA

Tel.: +91-22-66635456 Fax:+91-22-66635460 Email. auro@aurolabs.com Web: www.aurolabs.com

ANNEXURE - I

| PART - I   |   |                           |                           |   |                           |                           | Rs. In Lakhs)           |
|--|---|---------------------------|---------------------------|---|---------------------------|---------------------------|-------------------------|
| STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTH ENDED 31ST DECEMBER 2017 |   |                           |                           |   |                           |                           |                         |
| Sr. No.  | Particulars   | 3 Months ended            | Preceding 3 Months ended  | Corresponding 3 Months ended in the Previous Year | Nine Months Ended         |                           | Previous Year Ended     |
|  |   | 31.12.2017<br>(Unaudited) | 30.09.2017<br>(Unaudited) | 31-12-2016<br>(Unaudited)                         | 31.12.2017<br>(Unaudited) | 31.12.2016<br>(Unaudited) | 31-03-2017<br>(Audited) |
| <b>1</b>   | <b>Income from Operations</b>   |                           |                           |   |                           |                           |                         |
|  | (a) Net Sales/Income from Operations (Net)  | 1227.33                   | 971.79                    | 725.29  | 2,951.58                  | 2,540.15                  | 3,547.47                |
| <b>2</b>   | <b>Other Income</b>   | 12.34                     | 13.76                     | 10.00   | 28.74                     | 32.10                     | 52.69                   |
| <b>3</b>   | <b>Total Revenue (1 + 2)</b>  | 1,239.67                  | 985.55                    | 735.29  | 2,980.32                  | 2,572.25                  | 3,600.16                |
| <b>4</b>   | <b>Expenses</b>   |                           |                           |   |                           |                           |                         |
|  | a. Consumption of raw material  | 586.79                    | 634.72                    | 403.53  | 1,800.86                  | 1,530.22                  | 2,006.36                |
|  | b. Purchase of Stock-in-trade   | 1.98                      | 0.85                      | 0.80  | 2.83                      | 0.80                      | 1.31                    |
|  | c. (Increase) / decrease in Finished Goods stock in trade and work in progress                  | 210.75                    | 9.15                      | 74.46   | 98.73                     | 245.23                    | 234.16                  |
|  | d. Employee benefits expense  | 68.56                     | 56.74                     | 62.30   | 197.62                    | 185.96                    | 308.08                  |
|  | e. Finance Cost   | 41.00                     | 32.93                     | 47.30   | 103.82                    | 123.72                    | 107.26                  |
|  | f. Depreciation and amortisation expenses   | 28.00                     | 23.00                     | 20.00   | 73.00                     | 60.00                     | 86.38                   |
|  | g Other Expenses  | 168.22                    | 139.92                    | 105.72  | 436.45                    | 335.35                    | 565.01                  |
|  | <b>Total Expenses (4)</b>   | 1,105.30                  | 897.31                    | 714.11  | 2,713.31                  | 2,481.28                  | 3,308.56                |
| <b>5</b>   | <b>Profit / (Loss) before exceptional and extraordinary items and tax (3 ± 4)</b>               | 134.38                    | 88.24                     | 21.18   | 267.01                    | 90.97                     | 291.60                  |
| <b>6</b>   | <b>Exceptional items</b>  |                           |                           | -   | -                         | -                         | -                       |
| <b>7</b>   | <b>Profit / (Loss) before extraordinary items and, tax (5 ± 6)</b>                              | 134.38                    | 88.24                     | 21.18   | 267.01                    | 90.97                     | 291.60                  |
| <b>8</b>   | <b>Extraordinary items</b>  | -                         | -                         | -   | -                         | -                         | -                       |
| <b>9</b>   | <b>Profit / (Loss) before tax (7 ± 8)</b>   | 134.38                    | 88.24                     | 21.18   | 267.01                    | 90.97                     | 291.60                  |
| <b>10</b>  | <b>Tax expense</b>  |                           |                           |   |                           |                           |                         |
|  | (a) Current tax expenses for current year   | -                         | -                         | -   | -                         | -                         | -                       |
|  | (b) MAT credit (where applicable)   | -                         | -                         | -   | -                         | -                         | -                       |
|  | (c) Defferered tax  | -                         | -                         | -   | -                         | -                         | 151.98                  |
| <b>11</b>  | <b>Profit / (Loss) for the period from continuing operation (9± 10)</b>                         | 134.38                    | 88.24                     | 21.18   | 267.01                    | 90.97                     | 139.62                  |
| <b>12</b>  | <b>Profit / (Loss) for discontinuing operations</b>   | -                         | -                         | -   | -                         | -                         | -                       |
| <b>13</b>  | <b>Tax expense of discontinuing operations</b>  | -                         | -                         | -   | -                         | -                         | -                       |
| <b>14</b>  | <b>Profit / (Loss) for discontinuing operation (after tax) (12 ± 13)</b>                        | 134.38                    | 88.24                     | 21.18   | 267.01                    | 90.97                     | 139.62                  |
| <b>15</b>  | <b>Other Comprehensive Income</b>   | (1.81)                    | (5.74)                    | (3.51)  | 1.88                      | (4.65)                    | (0.94)                  |
| <b>16</b>  | <b>Total Comprehensive Income for the period (14 ± 15)</b>                                      | 132.57                    | 82.50                     | 17.67   | 268.89                    | 86.32                     | 138.68                  |
| <b>17</b>  | <b>Paid-up equity share capital</b><br>(Face value of Rs. 10 each)                              | 623.25                    | 623.25                    | 623.25  | 623.25                    | 623.25                    | 623.25                  |
| <b>17</b>  | <b>Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year</b> | -                         | -                         | -   | -                         | -                         | 376.71                  |
| <b>18</b>  | <b>Earnings per share (EPS) (Face Value - Rs. 10 per Equity Shares):</b>                        |                           |                           |   |                           |                           |                         |
|  | (a) Basic   | 2.16                      | 1.42                      | 0.34  | 4.28                      | 1.46                      | 2.24                    |
|  | (b) Diluted   | 2.16                      | 1.42                      | 0.34  | 4.28                      | 1.46                      | 2.24                    |

FOR & BEHALF OF BOARD OF DIRECTORS  
FOR AURO LABORATORIES LIMITED

  
SHARAT DEORAH  
CHAIRMAN & MANAGING DIRECTOR.  
DIN NO. 00230784

Place : Mumbai  
Date : 07.02.2018

**AURO LABORATORIES LIMITED**

**Notes:**

- 1) The above unaudited financial results for the quarter ended 31st December, 2017 were reviewed by the Audit Committee and there after approved at the meeting of the Board of Directors of the Company held on 7th February, 2018.
- 2) The Company had adopted Indian Accounting Standards (Ind AS) prescribed under section 133 of the Companies Act, 2013, read with the relevant rules issued thereunder. The date of transition to Ind AS is 1st April, 2017 and accordingly these unaudited financial results have been prepared in accordance with recognition and measurement principles laid down in Ind. AS 34 "Interim Financial Reporting" and the other accounting principles generally accepted in India. The impact of transition had been accounted for in the opening reserves and comparative period figures have been reinstated accordingly.
- 3) The Company has only one segment of activity namely "Pharmaceuticals".
- 4) Limited review has been carried out by the Statutory Auditors of the Company
- 5) Figures of previous period have regrouped / reclassified wherever necessary to facilitate comparison.
- 6) There is a possibility that these quarterly financial results may require adjustment before constituting the Final Ind AS financial statements as on the year ending March 31, 2018 due to changes in financial reporting requirements arising from new or revised standards or interpretations issued by MCA or changes in the use of one or more optional exemptions from full retrospective application as permitted under Ind AS 101.
- 7) The reconciliation of Net Profit reported in accordance with Indian GAAP to total comprehensive income in accordance with Ind. AS for the Quarter / Nine Months and year ended is as under.

| Particulars   | Rs. In Lacs        |              |              |                                   |                          |
|---|--------------------|--------------|--------------|-----------------------------------|--------------------------|
|   | for the qtr. ended |              |              | for the<br>nine<br>month<br>ended | for the<br>year<br>ended |
|   | 31.12.2016         | 30.09.2016   | 30.06.2016   | 31.12.2016                        | 31.03.2017               |
| Profit / (Loss) under previous GAAP                 | 20.78              | 21.26        | 50.30        | 92.34                             | 140.34                   |
| Ind. AS adjustment:                                 |                    |              |              |                                   |                          |
| Profit / (Loss) on Investment measure at fair value | 0.40               | 0.25         | (2.02)       | (1.37)                            | (0.72)                   |
| <b>Profit / (Loss) under Indian AS</b>              | <b>21.18</b>       | <b>21.51</b> | <b>48.28</b> | <b>90.97</b>                      | <b>139.62</b>            |
| Other Comprehensive Income                          | (3.51)             | (5.45)       | 4.31         | (4.65)                            | (0.94)                   |
| <b>Total Comprehensive Income for the period</b>    | <b>17.67</b>       | <b>16.06</b> | <b>52.59</b> | <b>86.32</b>                      | <b>138.68</b>            |

FOR & BEHALF OF BOARD OF DIRECTORS  
FOR AURO LABORATORIES LIMITED

  
SHARAT DEORAH  
CHAIRMAN & MANAGING DIRECTOR.  
DIN NO. 00230784

Place : Mumbai  
Date : 07.02.2018



**KHURDIA JAIN & CO.**  
CHARTERED ACCOUNTANTS

To,  
The Board of Directors,  
Auro Laboratories Limited.


We have reviewed the standalone Ind AS financial results of Auro Laboratories Ltd. ("the company") for the period ended December 31, 2017, attached herewith, being submitted by the company pursuant to the requirement of regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Financial results for the period ended December 31, 2017 have been prepared on the basis of interim financial statements which are responsibility of the Company's Management. Our responsibility is to issue a report on these financial results based on our review of such interim financial statements.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

The financial results for the period December 31, 2017, included in the statements, are based on the previously issued financial results of the company, prepared in accordance with the Accounting Standards specified under section 133 of the Companies Act, 2013 read with relevant Rules issued there under, which are reviewed by M/s. Kothari Jain & Associates Chartered Accountants, whose report dated February 10, 2017 express unmodified opinion on those unaudited standalone financial results. Management has adjusted these results for the differences in the accounting principles adopted by the Company on transition to the Indian Accounting Standard ('IND AS') and presented a reconciliation of profit under IND AS of the corresponding period with the profit reported under previous GAAP, which have been approved by the Company's Board of Directors but have not been subjected to a limited review.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statements prepared in accordance with generally accepted accounting standards in India and other recognized accounting practices and policies has not disclosed the information required to be disclosed in term of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, including the manner in which it is to be disclosed or that it contains any material misstatement.

For Khurdia Jain & Co.  
Chartered Accountants



Sampat Khurdia  
Partner  
Membership No. 33615  
Firm Reg. No. 120263W  
Place: Mumbai  
Date: 07/02/2018